Accelerating to Zero Coalition

Accelerating to Zero Coalition
Name	Accelerating to Zero Coalition
Formation	2015
Founder	Elton John Foundation; amfAR; International AIDS Society
Type	Coalition
Headquarters	New York City
Region served	Global
Focus	HIV/AIDS elimination

Accelerating to Zero Coalition The Accelerating to Zero Coalition is an international public–private partnership formed to hasten the end of the AIDS epidemic through combination prevention, testing, treatment, and policy change. It convenes a diverse set of actors from nonprofit organizations, pharmaceutical companies, research institutions, global health agencies, and philanthropic foundations to coordinate resources and advocacy toward ambitious targets for HIV incidence reduction. The Coalition operates at the intersection of clinical research, global health diplomacy, and community-led service delivery to translate scientific advances into measurable declines in new HIV infections.

Background and Formation

The Coalition emerged amid growing momentum from landmark initiatives and institutions including the Joint United Nations Programme on HIV/AIDS, the World Health Organization, and the Global Fund to Fight AIDS, Tuberculosis and Malaria, drawing on advocacy legacies from the Elton John AIDS Foundation, amfAR, and the International AIDS Society. Its founding was influenced by precedent efforts such as the President's Emergency Plan for AIDS Relief and the targets set at the United Nations General Assembly Special Session on HIV/AIDS. Key policy and research catalysts included breakthroughs reported by teams at Johns Hopkins University, University College London, and University of California, San Francisco demonstrating the preventive impact of antiretroviral therapy and pre-exposure prophylaxis studies like those led by investigators at Fred Hutchinson Cancer Research Center and University of KwaZulu-Natal. Early convenings included representatives from the Bill & Melinda Gates Foundation, the Clinton Health Access Initiative, and national ministries of health from high-burden countries such as South Africa, Kenya, and Uganda.

Mission and Goals

The Coalition’s stated mission centers on accelerating progress toward zero new HIV infections, zero discrimination, and zero AIDS-related deaths, aligning with global targets from UNAIDS and the Sustainable Development Goals. Strategic goals incorporate scale-up of antiretroviral therapy pathways validated by trials at Imperial College London and operational research from institutions like Médecins Sans Frontières and PATH. Targets emphasize expansion of testing platforms championed by Centers for Disease Control and Prevention programs, adoption of biomedical prevention tools such as pre-exposure prophylaxis advanced by researchers at University of Washington, and elimination of legal and structural barriers highlighted by reports from Human Rights Watch and Amnesty International.

Membership and Partnerships

Membership spans multinational pharmaceutical firms, civil society networks, research consortia, and multilateral agencies, featuring organizations such as Gilead Sciences, ViiV Healthcare, Pfizer, and Merck & Co. alongside advocacy groups like Treatment Action Campaign and Global Network of People Living with HIV. Academic partners include London School of Hygiene & Tropical Medicine, Columbia University, and Harvard T.H. Chan School of Public Health. Collaborative partnerships involve funders and implementers such as the Global Fund, PEPFAR, and bilateral agencies like USAID and DFID (now part of Foreign, Commonwealth & Development Office). The Coalition also engages municipal and provincial governments exemplified by alliances with health departments in New York City and KwaZulu-Natal.

Initiatives and Programs

Programmatic activity emphasizes rapid scale-up of testing, treatment, and prevention through coordinated campaigns, demonstration projects, and policy advocacy. Flagship initiatives have supported community-based testing models piloted in partnership with Community-Based Organizations affiliated with networks similar to UNAIDS key population platforms, and implementation science projects in collaboration with Bill & Melinda Gates Foundation-funded consortia. Biomedical priorities include accelerating access to long-acting injectables developed by teams at ViiV Healthcare and clinical trial networks like INSIGHT, while service delivery pilots draw on differentiated care models promoted by Institute for Healthcare Improvement and Médecins Sans Frontières. Advocacy strands engage legal reform efforts documented by Open Society Foundations and stigma reduction campaigns aligned with the Elton John AIDS Foundation.

Impact and Outcomes

The Coalition reports contributions to expanded access to antiretroviral therapy and increased uptake of pre-exposure prophylaxis in targeted locales, paralleling national trends reported by UNAIDS and surveillance data from WHO regional offices. Specific outcomes include facilitating partnerships that lowered procurement barriers through mechanisms similar to those used by the Global Fund and accelerating demonstration projects that informed policy shifts in countries such as Brazil, Thailand, and South Africa. The Coalition’s convening role has influenced dialogues at major fora including the International AIDS Conference and policy briefs circulated at United Nations General Assembly high-level meetings, shaping donor priorities and implementation guidelines used by agencies such as CDC and UNICEF.

Criticisms and Challenges

Critiques have focused on challenges typical of multi-stakeholder coalitions: balancing private-sector involvement with public-interest priorities, ensuring equitable representation of key populations advocated by groups like Treatment Action Campaign and Global Network of People Living with HIV, and measuring attribution of impact amid concurrent national programs by entities such as PEPFAR and the Global Fund. Operational challenges include sustaining financing in the context of shifting donor landscapes exemplified by budgetary debates in United States Congress and adapting to scientific uncertainties highlighted in trial results from institutions such as Harvard and Oxford University. Observers from Human Rights Watch and academic commentators have urged greater transparency in governance and more explicit accountability metrics tied to the targets set by UNAIDS.

Category:HIV/AIDS organizations